Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure

被引：0
|
作者：
Jonathan D. Ravid
Luke J. Laffin
机构：
[1] Cleveland Clinic Foundation,Internal Medicine Residency Program
[2] Cleveland Clinic Foundation,Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine
来源：
Current Cardiology Reports | 2022年 / 24卷
关键词：
Finerenone; Mineralocorticoid receptor; Chronic kidney disease (CKD); Hypertension; Albuminuria; Heart failure;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1251 / 1259
页数：8
相关论文
共 50 条
  • [1] Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure
    Ravid, Jonathan D.
    Laffin, Luke J.
    CURRENT CARDIOLOGY REPORTS, 2022, 24 (10) : 1251 - 1259
  • [2] Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
    Shah, Monarch
    Awad, Alaa S.
    Abdel-Rahman, Emaad M.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [3] Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease
    Lima Posada, Ixchel
    Soulie, Matthieu
    Stephan, Yohan
    Palacios Ramirez, Roberto
    Bonnard, Benjamin
    Nicol, Lionel
    Pitt, Bertram
    Kolkhof, Peter
    Mulder, Paul
    Jaisser, Frederic
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (12): : e032971
  • [4] Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease
    Raj, Rajesh
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2022, 31 (03): : 265 - 271
  • [5] The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances
    Xinping Chen
    Xuan Li
    Kexin Zhang
    Kexin Lian
    Wenqiang Zhang
    Yixin Song
    Chengxia Kan
    Jingwen Zhang
    Fang Han
    Xiaodong Sun
    Zhentao Guo
    Clinical and Experimental Nephrology, 2024, 28 : 125 - 135
  • [6] The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances
    Chen, Xinping
    Li, Xuan
    Zhang, Kexin
    Lian, Kexin
    Zhang, Wenqiang
    Song, Yixin
    Kan, Chengxia
    Zhang, Jingwen
    Han, Fang
    Sun, Xiaodong
    Guo, Zhentao
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2024, 28 (02) : 125 - 135
  • [7] The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges
    Yang, Pingping
    Huang, Tianlun
    Xu, Gaosi
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (09): : 1342 - 1349
  • [8] Finerenone: Efficacy of a New Nonsteroidal Mineralocorticoid Receptor Antagonist in Treatment of Patients With Chronic Kidney Disease and Type 2 Diabetes
    Dey, Subo
    Garg, Jasmine
    Wang, Andy
    Holzner, Eva
    Frishman, William H.
    Aronow, Wilbert S.
    CARDIOLOGY IN REVIEW, 2024, 32 (03) : 285 - 288
  • [9] Finerenone: a breakthrough mineralocorticoid receptor antagonist for heart failure, diabetes and chronic kidney disease
    Pradhan, Akshyaya
    Tripathi, Umesh Chandra
    EGYPTIAN HEART JOURNAL, 2024, 76 (01):
  • [10] Evidence for the use of a nonsteroidal mineralocorticoid receptor antagonist for the treatment of chronic kidney disease
    Plicas, Mariana Morais David
    da Silva, Bernardo Marques
    de Almeida, Edgar Avito Fernandes
    NEFROLOGIA, 2025, 45 (03): : 214 - 227
12345